Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 10—October 2023
Research

Comprehensive Case–Control Study of Protective and Risk Factors for Buruli Ulcer, Southeastern Australia

Bridgette J. McNamaraComments to Author , Kim R. Blasdell, Arvind Yerramilli, Ina L. Smith, Simone L. Clayton, Michael Dunn, Ee Laine Tay, Katherine B. Gibney, Nilakshi T. Waidyatillake, Mohammad A. Hussain, Michael Muleme, Daniel P. O’Brien1, and Eugene Athan1
Author affiliations: Barwon Health, Geelong, Victoria, Australia (B.J. McNamara, A. Yerramilli, M.A. Hussain, M. Muleme, D.P. O’Brien, E. Athan); University of Melbourne, Melbourne, Victoria, Australia (B.J. McNamara, K.B. Gibney, N.T. Waidyatillake, D.P. O’Brien); Commonwealth Scientific and Industrial Research Organisation, Geelong (K.R. Blasdell, S.L. Clayton, M. Dunn); Commonwealth Scientific and Industrial Research Organisation, Canberra, Australian Capital Territory, Australia (I.L. Smith); Department of Health, Melbourne (E.L. Tay); Peter Doherty Institute for Infection and Immunity, Melbourne (K.B. Gibney); Deakin University, Waurn Ponds, Victoria, Australia (N.T. Waidyatillake, E. Athan)

Main Article

Figure 3

Odds of developing Buruli ulcer according to different host factors in comprehensive case–control study of protective and risk factors for Buruli ulcer, southeastern Australia. Host characteristics are shown for case-patients and control participants as no. (%). Odds ratios (adjusted according to age and sex) and 95% CIs are indicated. Vaccination was with Mycobacterium bovis BCG vaccine for tuberculosis. Immunocompromised conditions category was for any participant who reported a condition that had the potential to compromise the immune system (excluding diabetes and cancer [active or historical]; cancer status was not available in this study). aOR, adjusted odds ratio; BCG, bacillus Calmette-Guérin vaccine; BU, Buruli ulcer.

Figure 3. Odds of developing Buruli ulcer according to different host factors in comprehensive case–control study of protective and risk factors for Buruli ulcer, southeastern Australia. Host characteristics are shown for case-patients and control participants as no. (%). Odds ratios (adjusted according to age and sex) and 95% CIs are indicated. Vaccination was with Mycobacterium bovis BCG vaccine for tuberculosis. Immunocompromised conditions category was for any participant who reported a condition that had the potential to compromise the immune system (excluding diabetes and cancer [active or historical]; cancer status was not available in this study). aOR, adjusted odds ratio; BCG, bacillus Calmette-Guérin vaccine; BU, Buruli ulcer.

Main Article

1These senior authors contributed equally to this article.

Page created: July 19, 2023
Page updated: September 20, 2023
Page reviewed: September 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external